Clario, a provider of endpoint data solutions for clinical trials, has formed a partnership with PathAI, a company specialising in AI-powered digital pathology, to offer an integrated solution for gastrointestinal (GI) clinical trials.
The collaboration combines anatomical pathology services with advanced video endoscopy analysis under a single vendor. This approach aims to streamline the process of managing endoscopic and histopathology data, potentially improving efficiency in global GI studies.
The integrated system covers aspects such as training, logistics, tissue processing, slide digitisation, image analysis, and data transfers, all under medical and scientific oversight.
Additionally, it aims to simplify workflows for clinical trial sites, offering enhanced training, reporting, and document management.
Clario’s gastroenterology medical director Marcela Vieira said: “At Clario we have long been at the forefront of supporting GI clinical trials, and we are excited to augment our strengths with PathAI’s capabilities in the area of discovery and patient care.
“The combination of endoscopy and histopathology promises to unlock new avenues for clinical research, and we are proud to be in this leadership position with our partners at PathAI.”
Clario brings considerable experience in gastrointestinal (GI) trials, having supported more than 130 studies using advanced imaging techniques such as endoscopy, MRI, and ultrasound. Their technologies, combined with AI-supported analysis for ulcerative colitis (UC) and high-definition video endoscopy, aim to reduce site workload and improve the efficiency of trials.
PathAI contributes to the partnership with its network of expert GI pathologists and advanced anatomical pathology services, focusing on improving specimen handling and histological assessments. Their AI-powered tools are designed to enhance the accuracy of UC evaluations, reduce variability in histological scoring, and accelerate biomarker discovery.
PathAI Biopharma chief business officer and president Matt Grow said: “We’re thrilled to partner with Clario to provide a cutting-edge solution for IBD clinical trials.
“Our collaboration will offer an integrated approach in histology and endoscopy for assessing therapeutic efficacy, accelerating biomarker discovery and therapy development in IBD.”
In September last year, Clario partnered with CellCarta to transform clinical trial sample management for histopathology studies.
The partnership seeks to improve the management of tissue and sample handling, as well as the subsequent digitisation process, to support clinical trial endpoint generation across various therapeutic areas, such as oncology, hepatology, and gastroenterology.
